TipRanks
Advertisement
Advertisement

CH:KYNB Stock Latest News

Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
Company AnnouncementsKyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
2d ago
8K
KYNB
Kyntra Bio appoints new independent director, updates governance
PremiumCompany Announcements
Kyntra Bio appoints new independent director, updates governance
7d ago
8K
KYNB
Kyntra Bio appoints Singer to its board of directors
PremiumThe Fly
Kyntra Bio appoints Singer to its board of directors
7d ago
KYNB
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
PremiumThe Fly
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
21d ago
KYNB
Kyntra Bio initiated with a Buy at Lake Street
PremiumThe Fly
Kyntra Bio initiated with a Buy at Lake Street
21d ago
KYNB
FibroGen Inc trading resumes
PremiumThe FlyFibroGen Inc trading resumes
28d ago
KYNB
FibroGen Inc trading halted, volatility trading pause
Premium
The Fly
FibroGen Inc trading halted, volatility trading pause
28d ago
KYNB
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
Premium
Company Announcements
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
1M ago
8K
KYNB
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
PremiumThe Fly
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
1M ago
KYNB
Kyntra Bio Earnings Call Highlights CD46 Oncology Push
PremiumCompany Announcements
Kyntra Bio Earnings Call Highlights CD46 Oncology Push
1M ago
KYNB
Kyntra Earns Buy Rating on Strong Cash Runway and Multiple Late-Stage Clinical Catalysts
PremiumRatings
Kyntra Earns Buy Rating on Strong Cash Runway and Multiple Late-Stage Clinical Catalysts
2M ago
KYNB
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
PremiumThe Fly
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
2M ago
KYNB
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status
PremiumCompany AnnouncementsKyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status
2M ago
KYNB
KYNB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
KYNB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
KYNB
Kyntra Bio initiated with an Outperform at Oppenheimer
Premium
The Fly
Kyntra Bio initiated with an Outperform at Oppenheimer
3M ago
KYNB
Kyntra Bio Shareholders Back Board, Pay and Auditor
PremiumCompany Announcements
Kyntra Bio Shareholders Back Board, Pay and Auditor
4M ago
8K
KYNB
Kyntra Bio to present additional MATTERHORN trial data at EHA
PremiumThe Fly
Kyntra Bio to present additional MATTERHORN trial data at EHA
4M ago
KYNB
Kyntra Bio Receives Final Payment for China Divestiture
PremiumCompany Announcements
Kyntra Bio Receives Final Payment for China Divestiture
4M ago
8K
KYNB
Kyntra Bio initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Kyntra Bio initiated with a Buy at Rodman & Renshaw
4M ago
KYNB
Kyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026
PremiumCompany AnnouncementsKyntra Bio Warned of Nasdaq Non‑Compliance, Faces Delisting Risk Without Remediation Plan by May 18, 2026
5M ago
KYNB
FibroGen Earnings Call Highlights Clinical Momentum, Runway
Premium
Company Announcements
FibroGen Earnings Call Highlights Clinical Momentum, Runway
5M ago
KYNB
Kyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
Premium
Ratings
Kyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
5M ago
KYNB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >